UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 4, 2004
---------------------------
GENELABS TECHNOLOGIES, INC.
- -------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
California 0-19222 94-3010150
- ------------------------------ -------------------------- ---------------------
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
505 Penobscot Drive, Redwood City, California 94063
- ------------------------------------------------------ ------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (650) 369-9500
---------------------------
- -------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of
the following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
2.02 Results of Operations and Financial Condition
On November 4, 2004, Registrant announced its financial results for
the fiscal quarter ended September 30, 2004 and made forward-looking
statements relating to the fourth quarter of fiscal year 2004. The press
release also provides unaudited condensed consolidated balance sheets
comparing September 30, 2004 and December 31, 2003. The press release provides
unaudited condensed consolidated statements of operations comparing the three
month and nine month periods ended September 30, 2004 and September 30, 2003.
A copy of the press release is furnished as exhibit 99.1 hereto.
The information in this Form 8-K (including Exhibit 99.1) shall not
be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934 (the "Exchange Act") or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing.
9.01 Financial Statements and Exhibits
(c) Exhibits.
99.1 Press Release of Registrant, dated November 4, 2004, entitled
"Genelabs Technologies, Inc. Reports Financial Results for the Third
Quarter and First Nine Months of 2004 and Provides Company Update"
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereto duly authorized.
GENELABS TECHNOLOGIES, INC.
By: /s/ Adrian Arima
-----------------------------------
Name: Adrian Arima
Title: Vice President, General Counsel
Date: November 4, 2004
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
---------- -----------
99.1 Press Release of Registrant, dated November 4,
2004, entitled "Genelabs Technologies, Inc.
Reports Financial Results for the Third Quarter
and First Nine Months of 2004 and Provides Company
Update"